WRassman,M.D. BaldingBlog
    • Menu

    Cure for hair loss coming soon?

    May 31, 2020/by William Rassman, M.D./0 /Hair Loss Causes

    HAIR GROWTH DRUG SEEN AS A WONDER FOR UPJOHN

    By John Crudele

    • May 28, 1985
    Credit…The New York Times Archives
    See the article in its original context from
    May 28, 1985, Section D, Page 1Buy Reprints

    The Upjohn Company may be several years away from receiving Government approval to sell what could be a revolutionary hair-growth ointment, but thousands of balding men are said to be using a homemade version of the product.

    And while the company is still a long way from seeing the full financial impact of its drug, called minoxidil, Upjohn may already be realizing considerable benefits from the cottage industry that has grown up around the compound.

    Minoxidil has the approval of the United States Food and Drug Administration, but as a tablet taken to treat hypertension. Years ago, however, Upjohn scientists found that the drug promoted hair growth as a side effect. More recently, doctors have been putting patients on minoxidil not to fight hypertension, but to grow hair.

    Dr. Michael Lorin Reed, assistant clinical professor of dermatology at the New York University Medical Center, said he had ”at least several hundred people on the drug right now.” Dr. Reed said there were a ”zillion people prescribing” minoxidil for hair growth.

    No Final Verdict on Product

    While such use by doctors is legal, the F.D.A. said, people might not get the desired results. Upjohn, meanwhile, has been contending that some sellers of the homemade product may be infringing on company patents.

    A question remaining about the drug’s use in combating baldness is whether it will be absorbed through the skin and produce unusually low blood pressure.

    While a debate is raging over how effective the drug will be against receding hairlines, Wall Street is unanimous in believing the product will be important for Upjohn.

    ”Topical minoxidil for male pattern baldness could become one of the largest selling drugs in the world and transform Upjohn into one of the fastest growing major domestic drug companies,” said Ronald M. Nordmann, an analyst at Oppenheimer & Company.

    Stock Soared Last Week

    The investment community’s excitement over the hair ointment was obvious last week when the mention of minoxidil in a routine report by another Wall Street analyst, Paul Brooke of Morgan Stanley & Company, sent Upjohn’s stock soaring $13.375 a share for the week to a final price of $110.25 on Friday.

    Mr. Nordmann believes minoxidil, if approved by the F.D.A. for external use, could generate about $500 million in annual sales for Upjohn and net income of $204 million. Upjohn’s total sales in 1984 were $2.18 billion and net earnings were $173.3 million.

    But Upjohn may already be seeing some benefits of minoxidil’s popularity for hair growth. While Upjohn will not disclose sales figures for any of its drugs, Mr. Nordmann estimated that sales of minoxidil tablets, under the brand name Loniten, would grow to about $30 million this year, from only $7 million in 1983. ”The growth is clearly not coming from the hypertension market,” he said.

    It was in the early 1970’s that Upjohn, a pharmaceutical company based in Kalamazoo, Mich., noticed that minoxidil tablets were causing hair growth in patients. In 1977 it began investigating whether the drug, when applied externally as a liquid, could arrest the balding process. An Upjohn spokeswoman said the results of the studies were not complete, but she added that the company expected to file for F.D.A. approval of the hair ointment later this year, beginning a licensing process that usually takes about two years.

    Cost Is $100 a Month

    But thousands of men apparently have sidestepped the barriers to using this drug, with the help of medical doctors.

    According to Dr. Reed, to convert minoxidil, the hypertension drug, into minoxidil, the hair treatment, 180 tablets are crushed and mixed with water, alcohol and propylene glycol.

    That produces two ounces of the hair growth formula, enough for a one-month supply. Rob Davis, a colleague of Mr. Nordmann at Oppenheimer and one of Dr. Reed’s patients, said the formula was applied nightly from an eyedropper, rubbed in and covered with a cap. The cost is $100 a month, he said.

    ”I think it’s worked fairly dramatically,” said Mr. Davis, who said his existing hair seems to have thickened, although new hair growth has been less dramatic. Dr. Reed agreed that minoxidil held more promise for making existing hair look fuller, rather than for causing new hair to sprout.

    According to a spokesman, Upjohn has been warning users that the ground-up tablets might produce different results from the ointment given to the volunteers in the Upjohn study. The F.D.A. agrees, said Bruce Brown, an agency spokesman, noting that the altered product ”may not bear any resemblance to the form that is under investigation.”

    In its tests, Upjohn said, it has found that one-third of the volunteers showed hair growth, while on another one-third there was light, fuzzlike growth. The remaining volunteers were not helped by the ointment.

    20 with early recession, what do I do? (photo)

    May 30, 2020/by William Rassman, M.D./0 /Hair Loss Causes

    Finasteride is a great drug for a 20 year old and with minoxidil and possibly dermrolling, you might reverse the loss. There have been many good examples of this on this blog.  Use the search engine and put in ‘finasteride’ ‘photo’ and see what comes up, I think that you will be impressed.

    Mature hairline photo

    May 29, 2020/by William Rassman, M.D./0 /Hair Loss Causes

    Notice its location is one finger breadth above the highest crease of the furrowed brow and the hairline takes a gentle V shape

    Hair Transplant Failure from Natural Hair Institute Istanbul (Photos 3 Years Apart)

    May 29, 2020/by William Rassman, M.D./0 /Hair Loss Causes

    BEFORE PHOTO                                   3 YEARS LATER

    This man had over 4000 FUE grafts and now his donor area is almost completely depleted.

    His only option is to remain bald or get Scalp Micropigmentation

    Attached below is his Warranty Certificate which guarantees growth (not honored)

    What Is Wrong with Me and What Can I Do About It? (Photo)

    May 29, 2020/by William Rassman, M.D./0 /Hair Loss Causes

    This is a case of Triangular Alopecia, an inherited bald area always located where you have it. Some people have it on both sides of their head. It is easily fixed with a hair transplant

    When to Take Finasteride?

    May 29, 2020/by William Rassman, M.D./0 /Hair Loss Causes

    Its a part of your routine and you’re less likely to forget it, you’ll always be near it when you get out of bed, etc. But for night it can also be a part of your nightly routine and during your sleep you won’t have time to hyper focus on whether youre feeling sides or not, but I can also imagine that with nothing to stimulate your mind you may wander to whether you’re feeling sides while if you take it in the day you’ll have stuff to occupy yourself so you maybe won’t think about it. 

    Makes no difference when you take it because it is not the blood level that works, but the tissue buildup in the hair follicles.

    Bald spot recently appeared (photo)

    May 29, 2020/by William Rassman, M.D./0 /Hair Loss Causes

    The sudden appearance of such a bald spot is suggestive of Alopecia Areata. See a dermatologist.

    Are my grafts coming out? (photo)

    May 29, 2020/by William Rassman, M.D./0 /Hair Loss Causes

    The person who put these grafts into your recipient area seems to have only put the bottom of the graft into the recipient wound. I see most of each graft actually not inside the skin where they belong.  I see quite a few grafts that seem to be already out as I zoomed into the photo. If this is what the ‘operator’ thinks is a quality hair transplant, they better go back to school and I am not sure how to help you at this late stage.  I would doubt that most of these grafts will survive.  There appears to be a great deal of work done and a good amount of your  donor area has been harvested which will impact your next experience significantly.

     

     

     

     

    [click to enlarge]

    Publication on Microneedling Suggests It Has No Value

    May 28, 2020/by William Rassman, M.D./0 /Hair Loss Causes

    Dr. Rassman’s Comment:  The study is small (15 patients) but the conclusion is significant that microneedling doesn’t help either grow hair or improve existing hairs. I don’t necessarily agree with the message delivered by these authors as we have been seeing considerable hair growth in many young men using microneedlin; nevertheless, I always strive to give both sides of the story.

    SOHAG MEDICAL JOURNAL Vol. 22 No.1 Jan 2018 369 Microneedling as a monotherapy in treatment of male androgenetic alopecia Essam A. Nada, RehamEzz El-Dawla, Wafaa M. Abd El-Maged Ashraf A. Abd El-Latif, Marwa A. Abo Elmagd, Department of Dermatology, Venereology and Andrology Introduction Androgenetic alopecia (AGA) is the result of progressive, patterned hair loss that occurs when genetically predisposed individuals are exposed to androgens.The psychosocial impact of AGA may negatively affect patient’s quality of life andcan lead to personal social and job-related problems (1) .

    Also; AGA can cause indirect physical harm to some patients, such as sunburn as a result of hair loss and exposure to ultraviolet light (2) .Moreover; AGA is reportedly associated with increased incidence of myocardial infarction, hypertension and hypercholesterolemia (3) . Drug therapies for AGA approved by the FDA are limited to topical minoxidil and oral FIN with efficacy varies between 40% and 60% (4) . Multiple factors are implicated in the pathogenesis of AGA which involves not only DHT but also inflammation, genes, signalling pathway, stimulatory pathways like Wnt/B catenin, and growth factors(5) . The existing conventional therapies (i.e. FIN and minoxidil) fail to target all of them (6) .

    Microneedling (MN) is a relatively new minimally invasive procedure involving controlled puncturing of the skin by rolling with miniature fine needles(7) . It showed efficacy in some dermatological conditions including post-acne scars (8) , other scars (9) , pigmentary disorders (10) , and as a method of drug delivery (11) . The demand for new treatment techniques for AGA is growing, various procedures like mesotherapy, MN, platelet rich plasma, low laser light therapy, and stem?celltherapy are under active investigation (12) . MN creates multiple microchannels and increases transdermal penetration of drugs, facilitating higher concentration in dermis (13) . Scalp needling also stimulates blood flow around blood starved hair follicles and gently exfoliates dead skin cells (14) .ScalpMN also induces hair regrowth by the following: release of growth factors through platelet activation and skin wound regeneration mechanism, activation of hair follicle stem cells in the hair bulge area under wound healing conditions which is caused by MN, and overexpression of hair growth-related genes, vascular endothelial growth factors, ? catenin, Wnt3a, and Wnt10 b as documented in animal studies(6) . The use of MN in combination with minoxidil showed promising results in treatment of AGA (6) . Furthermore; the addition of MN to minoxidil and oral FIN improved AGA in patients who were resistant to minoxidil and oral FIN (15) . To the best of our knowledge; the use of MN as monotherapy hasn`t been previously reported.This study was designed to evaluate the efficacy and safety ofMN as a monotherapy in treatment of male AGA.

    Patients and methods: After approval of this study by Ethical and Research committees at Faculty of Medicine, Sohag University;15 male patients complaining of progressive hair loss diagnosed as AGA were included.All patients assigned informed written consent. Exclusion criteria Exclusion criteria included patients with other forms of alopecia including telogen effluvium, alopecia areata, those with dermatological or systemic illness known to cause diffuse hair loss (as thyroid disorders or anemia), and patients received minoxidil, any hair growth promoters in the past six months or those underwent surgical hair transplantation. SOHAG MEDICAL JOURNAL Microneedling as a monotherapy in treatment Vol. 22 No.1 Jan 2018 Marwa A. Abo Elmagd 370 Patients on hormonal, androgenic or anti androgenic medications cytotoxic, and inhibitors of CYP3A4 (ketoconazole, verapamil, diltiazem, cimetidine, ciprofloxacin), and those on anticoagulant medications (aspirin, warfarin and heparin) or have skin disease with Koebner’s phenomenon were also excluded.

    Methods:All patients were subjected to: I- Initial evaluation Personal history was reported including the age, occupation, marital status, smoking, and residency. History of hair loss was discussed with all patients including onset, course and duration of hair loss, site of hair loss, and use of hair care cosmetics (dying, bleaching, and straightening).History of other skin diseases, systemic diseases or any medications was documented. Family history of a similar condition was reported. Full general examinationwas done searching for any signs of anemia. Scalp examination was performed as regards any signs of inflammation, scales, erythema or scarring. II- Evaluation of hair loss: II.1- Pull test:After instructing the patient not to wash hair for 24 hours; grasping a small clump about 60 hairs in the index, middle and thumb was done, with pulling hairs gently but with firm pressure. The shed hairs were counted and positive test was reported as more than 6 hairs shed (16) . II.2- Grading of AGAaccording to Norwood-Hamilton scale(17) . II.

    3- Digital photography: The patients were photo documented before and after six months of treatment. A picture of the frontoparietal region was obtained in each patient. Before the photograph was taken the patient’s hair was combed in a consistent manner for each patient so that the balding area could be optimally viewed. II.4- Trichoscopy: An epiluminescene digital microscope (compareview A/V; Version 1.5.09) was used in this study. Trichoscope has five magnification lenses of different magnification powers which are x15, x30, x 50, x150 and x200 folds.A magnification of (x 50) was used to detect the density of the hair follicles, vellus and terminal hairs; while magnification of (x 200) was used to evaluate the caliber of the hair shaft. The frontal area of the scalp of each patient underwent tricoscopic evaluation, before and six months after treatment (frontal area was defined as approximately 2 cm from the frontal hairline and 2 cm from the midline(18) . Trichoscopic images were taken at the same specific area in the frontal area of each patient. III- Treatment procedues:Microneedling was done using dermapen. Dermapen is auto-stamp motorized meso machine; it is a pen like instrument with a handle, a disposable needle cartridge, having 12 needles arranged in rows, and a power button to turn the machine on and off. It has guides to adjust needle length (turning the guide clockwise, the needle length will be longer ranging from (0.25 mm to 2 mm maximum). Topical anesthesia with 4% lidocaine cream was carried out 30 minutes before the procedure to the frontal area of the scalp of each patient, after this period, the cream was removed with saline, and the antisepsis of the entire area to be treated was subsequently performed with alcoholic chlorhexidine. Then the area had been completely dried. The affected area of the scalp was stretched and MN was carried out in vertical and horizontal directions for about four to five times, until mild erythema was noted. The used needle length was 1.25 mm.

    Treatment schedule: 13 sessions were done for each patient according to the following schedule: ? Once every week for eight weeks (week 0, 1, 2, 3, 4, 5, 6, 7). ? Once every two weeks for one month (week 9, 11). ? Once every month for three months (week 15, 19, 23). IV- Treatment assessment: Assessment was done monthly and one week after the last session (24th week) depending on: IV.1) Grading scale: according to NorwoodHamilton grading scale. SOHAG MEDICAL JOURNAL Microneedling as a monotherapy in treatment Vol. 22 No.1 Jan 2018 Marwa A. Abo Elmagd 371 IV.2) Photographic assessment: Digital photos of the affected region were obtained from patients before starting treatment (baseline) and at the end of treatment . IV.3) Phototrichoscope: All patients underwent trichoscopic evaluation. Hair images were taken at 50x and 200x fold magnifications at the same affected area in the scalp of each patient before and after six months of treatment with (measurements of the hair density, hair thickness and terminal/vellus hair ratio(. IV.4)

    Patient’s self-assessment (Hair growth questionnaire):Patients assessed their scalp hair at the end of the study using a validated hair growth questionnaire containing four questions on treatment efficacy and three questions on satisfaction with appearance (19) (Figure I). Figure I: Patient self-assessment questionnaire concerning changes in their scalp hair after treatment (19) . IV.5) Investigator assessment: The hair density in the fronto-parietal region was compared to that observed before treatment using a 7-point rating scale: greatly decreased (-3), moderately decreased (-2), slightly decreased (-1), no change (0), slightly increased (+1), moderately increased (+2), and greatly increased (+3)(20) . IV.6) Safety and tolerability assessment: Any side effects reported by the patient or noticed by the investigator was recorded. Statistical analysis: ? Data was analyzed using STATA intercooled version 12.1. ? Numerical data were presented as mean and standard deviation (SD) values, for parametric numerical data, while Median and range for non-parametric numerical data. ? For parametric data: Paired t-test was used to assess the statistical significance of the difference between two means measured twice. ? For non-parametric data: Wilcoxon signed rank test was used assess the SOHAG MEDICAL JOURNAL Microneedling as a monotherapy in treatment Vol. 22 No.1 Jan 2018 Marwa A. Abo Elmagd 372 statistical significance of the difference of non-parametric variables measured twice Results

    The study included 15 male patients diagnosed as having AGA.The mean age± SD of the patients was 25.73±4.27 years, with 10 (66.67%) of them from rural areas.Family history of AGA was positive in 8 (53.33%) of the patients.Most of the patients 13 (86.67%) showed gradual onset of hair loss and progressive course was reported in all patients with mean disease duration ± SDwas 4.33±2.23 years.The highest prevalence of hair loss was in the frontal and vertex regions (53.33%).Only 2 patients (13.33%) had positive pull test and scales were found in 3 patients (20%). There was small decline in hair density but with no significant difference between hair density at the baseline and at 6th month.There was no significant difference between hair caliber at the baseline and at 6th month.There was mild increase in terminal/vellus ratio, with no significant difference between terminal/vellus ratio at the baseline and at 6th month (Table 1). Table 1: Results of phototrichoscopeof the study population (n= 15) before and after treatment. Variables At baseline After treatment Change Percent of change *P value Hair density: Mean ± SD Median (range) 189.07±143.1 187.5 (6-467) 180±130.48 150 (12-410) [-9.07]±30.30 0.5 ([-87]-22) -4% 0.65 Hair Caliber: Mean ± SD Median (range) 0.020±0.016 0.018 (0.001-0.05) 0.020±0.013 0.015 (0.004-0.045) 0.0003±0.015 0.001 ([-0.027]-0.031) 3% 0.69 Terminal/vellushair ratio: Mean ± SD Median (range) 2.72±3.88 1.75 (0.14-15.4) 2.89±5.06 1.45 (0.13-20) 0.17±1.40 -0.005 ([-1.3]-4.6) 4% 0.73 * P value <0.05 was significant. As regards the investigator assessment; 13/15 (86.67%) of the patients showed no change in hair density, one patient (6.67%) showed slight increase, and the last patient (6.67%) showed slight decrease. Results of the patient self-assessment questionnaire are shown in table 2. The only side effect was pain, which was reported in 10(66.67%) of the patients.

    Table 2: Results of the patient self-assessment questionnaire in the study groups (n=15). Variables Frequency (Percentage) Variables Frequency (Percentage) 1) Bald spot getting smaller: Agree No opinion either way Disagree Strongly disagree 0 1 (6.67%) 7 (46.67%) 7 (46.67%) 2) Appearance of hair: Somewhat better A little better Same A little worse 0 2 (13.33%) 10 (66.67%) 3 (20.00%) 3) Hair growth: Greatly increased Moderately increased Slightly increased No change Slightly decreased 0 0 6 (40.00%) 7 (46.67%) 2 (13.33%) 4) Slowing down hair loss: Very effective Somewhat effective Not very effective Not effective at all 0 2 (13.33%) 8 (53.33%) 5 (33.33%) 5) Satisfaction about hairline at the front of the head: Very satisfied Satisfied Neutral Dissatisfied Very dissatisfied 0 0 3 (20.00%) 2 (13.33%) 10 (66.67%) 6) Satisfaction about hair on the top: Very satisfied Satisfied Neutral Dissatisfied Very dissatisfied 0 0 0 10 (66.67%) 5 (33.33%) 7) Hair overall satisfaction: Very satisfied Satisfied Neutral Dissatisfied Very dissatisfied 0 0 0 10 (66.67%) 5 (33.33%) SOHAG MEDICAL JOURNAL Microneedling as a monotherapy in treatment Vol. 22 No.1 Jan 2018 Marwa A. Abo Elmagd 373

    Discussion The presence of AGAhas its negative effects on the patient’s quality of life(1) .As multiple factors are implicated in the pathogenesis of AGA and the existing conventional therapies (i.e. FIN and minoxidil) fail to target all of them; the demand for new treatment techniques for AGA is growing.MN is one of these techniques that showed promising results in treatment of male AGA (6, 15) . In the current study; there was statistically insignificant decrease in hair density with mean percentage of change (-4%) after treatment. This decrease can be taken as the “normal” hair loss with AGA, so patients go bald despite therapy. On the contrary; increased hair count was previously reported with use of MN in male AGA(6) . Authors found that MN along with minoxidil-treated group was statistically superior to minoxidil alone-treated group in promoting hair growth in men. The mean change in hair count after 3 months was significantly greater for the MN group compared to the minoxidil group (91.4 versus 22.2 respectively)(6) . This may be related to the value of MN as drug delivery method rather than mechanical effect. Concerning hair shaft diameter in the present study; there was minimal statistically insignificant increase with mean percentage of change (3%).The increase in the hair shaft diametergoes with the alleged role of trauma of MN in improvement of AGA.These results were consistent with a previous report of mild statistically insignificant increase in mean hair shaft diameter in patients receiving mesotherapy with saline, this goes with the alleged role of trauma of mesotherapy injection in improvement of AGA(21) . Concerning terminal/ vellus ratio;there was 4% mean percentage of change, which was mild and not statistically significant.The minimal improvement noticed might be attributed to stimulation of hair growth by the trauma which increases the blood supply to the HF, but it was minimal and not clinically or statistically significant

    References 1. Hunt N and Mchale S: The psychological impact of alopecia.BMJ. 2005; 331(7522): 951-3. 2. Gubelin Harcha W, Barboza Martinez J, Tsai TF, Katsuoka K, Kawashima M: A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia.J Am Acad Dermatol. 2014; 70(3): 489-98.e3. 3. Kim MW, Shin IS, Yoon HS, Cho S and Park HS: Lipid profile in patients with androgenetic alopecia: a meta-analysis.J Eur Acad Dermatol Venereol. 2017; 31(6): 942-51. 4. Gkini MA, Kouskoukis AE, Tripsianis G, Rigopoulos D and Kouskoukis K: Study of platelet-rich plasma injections in the treatment of androgenetic alopecia through an one-year period.J Cutan Aesthet Surg. 2014; 7(4): 213-9. 5. Leiros GJ, Attorresi AI and Balana ME: Hair follicle stem cell differentiation is inhibited through cross-talk between Wnt/beta-catenin and androgen signalling in dermal papilla cells from patients with androgenetic alopecia.Br J Dermatol. 2012; 166(5): 1035-42. 6. Dhurat R, Sukesh M, Avhad G, Dandale A, Pal A: A randomized evaluator blinded study of effect of microneedling in androgenetic alopecia: a pilot study.Int J Trichology. 2013; 5(1): 6-11. 7. Fertig RM and Gamret AC: Microneedling for the treatment of hair loss? 2017. 8. Ayatollahi A, Hosseini H, Shahdi M, Ahmadnasrollahi S, Nassirikashani M: Platelet-rich Plasma by Single Spin Process in Male Pattern Androgenetic Alopecia: Is it an Effective Treatment? Indian Dermatol Online J. 2017; 8(6): 460-464. 9. Costa IM and Costa MC: Microneedling for varicella scars in a dark-skinned teenager.Dermatol Surg. 2014; 40(3): 333-4. SOHAG MEDICAL JOURNAL Microneedling as a monotherapy in treatment Vol. 22 No.1 Jan 2018 Marwa A. Abo Elmagd 374 10. Budamakuntla L, Loganathan E, Suresh DH, Shanmugam S, Suryanarayan S: A Randomised, Open-label, Comparative Study of Tranexamic Acid Microinjections and Tranexamic Acid with Microneedling in Patients with Melasma.J Cutan Aesthet Surg. 2013; 6(3): 139-43. 11. Iriarte C, Awosika O, Rengifo-Pardo M and Ehrlich A: Review of applications of microneedling in dermatology.Clin Cosmet Investig Dermatol. 2017; 10: 289-98. 12. Motofei IG, Rowland DL, Baconi DL, Tampa M, Sarbu MI: Androgenetic alopecia; drug safety and therapeutic strategies.Expert Opin Drug Saf. 2018. 13. Escobar-Chavez JJ, Bonilla-Martinez D, Villegas-Gonzalez MA, Molina-Trinidad E, Casas-Alancaster N: Microneedles: a valuable physical enhancer to increase transdermal drug delivery.J Clin Pharmacol. 2011; 51(7): 964-77. 14. Matarasso A, Pfeifer TM and Plastic Surgery Educational Foundation DC: Mesotherapy for body contouring.Plast Reconstr Surg. 2005; 115(5): 1420-4. 15. Dhurat R and Mathapati S: Response to Microneedling Treatment in Men with Androgenetic Alopecia Who Failed to Respond to Conventional Therapy.Indian J Dermatol. 2015; 60(3): 260-3. 16. Shapiro J, Wiseman M and Lui H: Practical management of hair loss.Can Fam Physician. 2000; 46: 1469-77. 17. Sehgal VN, Kak R, Aggarwal A, Srivastava G and Rajput P: Male pattern androgenetic alopecia in an Indian context: a perspective study.J Eur Acad Dermatol Venereol. 2007; 21(4): 473-9. 18. Hillmann K and Blume-Peytavi U: Diagnosis of hair disorders.Semin Cutan Med Surg. 2009; 28(1): 33-8. 19. Barber B, Kaufman K, Kozloff R, Girman C and Guess H: A hair growth questionnaire for use in the evaluation of therapeutic effects in men.J Dermatol Treat. 1998; 9(3): 181-186. 20. Lucky AW, Piacquadio DJ, Ditre CM, Dunlap F, Kantor I: A randomized, placebocontrolled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss.J Am Acad Dermatol. 2004; 50(4): 541-53. 21. Sobhy N, Aly H, El Shafee A and El Deeb M: Evaluation of the effect of injection of dutasteride as mesotherapeutic tool in treatment of androgenetic alopecia in males.Our Dermatol Online. 2013; 4(1): 40-5.1. Muller DC, Giles GG, Sinclair R, Hopper JL, English DR: Agedependent associations between androgenetic alopecia and prostate cancer risk.Cancer Epidemiol Biomarkers Prev. 2013; 22(2): 209-15. 22. Hunt N and Mchale S: The psychological impact of alopecia.BMJ. 2005; 331(7522): 951-3. 23. Gubelin Harcha W, Barboza Martinez J, Tsai TF, Katsuoka K, Kawashima M: A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia.J Am Acad Dermatol. 2014; 70(3): 489- 498.e3. 24. Kim MW, Shin IS, Yoon HS, Cho S and Park HS: Lipid profile in patients with androgenetic alopecia: a meta-analysis.J Eur Acad Dermatol Venereol. 2017; 31(6): 942-951. 25. Gkini MA, Kouskoukis AE, Tripsianis G, Rigopoulos D and Kouskoukis K: Study of platelet-rich plasma injections in the treatment of androgenetic alopecia through an one-year period.J Cutan Aesthet Surg. 2014; 7(4): 213-9. 26. Dhurat R, Sukesh M, Avhad G, Dandale A, Pal A: A randomized evaluator blinded study of effect of microneedling in androgenetic alopecia: a pilot study.Int J Trichology. 2013; 5(1): 6-11. 27. Arif T, Dorjay K, Adil M and Sami M: Dutasteride in Androgenetic Alopecia: An Update.Curr Clin Pharmacol. 2017; 12(1): 31-35. 28. Abdallah M, El-Zawahry K and Besar H: Mesotherapy using dutasteride-containing solution in male pattern hair loss: A controlled pilot study.J Pan Arab Leag Dermatol. 2009; 20: 137-45. SOHAG MEDICAL JOURNAL Microneedling as a monotherapy in treatment Vol. 22 No.1 Jan 2018 Marwa A. Abo Elmagd 375 29. Sobhy N, Aly H, El Shafee A and El Deeb M: Evaluation of the effect of injection of dutasteride as mesotherapeutic tool in treatment of androgenetic alopecia in males.Our Dermatol Online. 2013; 4(1): 40-5. 30. Saceda-Corralo D, Rodrigues-Barata AR, Vano-Galvan S and Jaen-Olasolo P: Mesotherapy with Dutasteride in the Treatment of Androgenetic Alopecia.Int J Trichology. 2017; 9(3): 143-145. 31. Fertig RM and Gamret AC: Microneedling for the treatment of hair loss? 2017. 32. Dhurat R and Mathapati S: Response to Microneedling Treatment in Men with Androgenetic Alopecia Who Failed to Respond to Conventional Therapy.Indian J Dermatol. 2015; 60(3): 260-3. 33. Shapiro J, Wiseman M and Lui H: Practical management of hair loss.Can Fam Physician. 2000; 46: 1469-77. 34. Sehgal VN, Kak R, Aggarwal A, Srivastava G and Rajput P: Male pattern androgenetic alopecia in an Indian context: a perspective study.J Eur Acad Dermatol Venereol. 2007; 21(4): 473-9. 35. Barber B, Kaufman K, Kozloff R, Girman C and Guess H: A hair growth questionnaire for use in the evaluation of therapeutic effects in men.J Dermatol Treat. 1998; 9(3): 181-186. 36. Lucky AW, Piacquadio DJ, Ditre CM, Dunlap F, Kantor I: A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss.J Am Acad Dermatol. 2004; 50(4): 541-53. 37. Mounsey AL and Reed SW: Diagnosing and treating hair loss.Am Fam Physician. 2009; 80(4): 356-62. 38. Andriole GL and Kirby R: Safety and tolerability of the dual 5alpha-reductase inhibitor dutasteride in the treatment of benign prostatic hyperplasia.Eur Urol. 2003; 44(1): 82-8. 39. Eun HC, Kwon OS, Yeon JH, Shin HS, Kim BY: Efficacy, safety, and tolerability of dutasteride 0.5 mg once daily in male patients with male pattern hair loss: a randomized, doubleblind, placebo-controlled, phase III study.J Am Acad Dermatol. 2010; 63(2): 252-8. 40. Amory JK, Wang C, Swerdloff RS, Anawalt BD, Matsumoto AM: The effect of 5alphareductase inhibition with dutasteride and finasteride on semen parameters and serum hormones in healthy men.J Clin Endocrinol Metab. 2007; 92(5): 1659-65. 41. Olsen EA: Female pattern hair loss.J Am AcadDermatol. 2001; 45(3 Suppl):s70-80 ?????? ?????? SOHAG MEDICAL JOURNAL Microneedling as a monotherapy in treatment Vol. 22 No.1 Jan 2018 Marwa A. Abo Elmagd 376

    Is There Really Any Difference B/W Getting a Transplant at 25 and 26? Especially If I’ve Been Taking Fin Consistently for a Year Already?

    May 28, 2020/by William Rassman, M.D./0 /Hair Loss Causes

    The age gap just seems pretty arbitrary. Not sure if I should wait or just go for it. Thanks!

    The issue here if you are 25, is what you have done prior to this time. Have you tried the drug finasteride? What has happened to your hair loss on the drug? This is the type of information I need besides your family history. I don’t want you to wake up one day and hate me if you became very bald one year after I did your hair transplant. I want to know as much as you do.

    Hair Banking Approved in the UK

    May 27, 2020/by William Rassman, M.D./0 /Hair Loss Causes

    https://www.businesscloud.co.uk/news/world-first-start-up-hairclone-launches-baldness-cure

    Of course, when reading this, it is holding on to hair for future cloning when and if it becomes available.  Interesting! I know the doctors involved in this project.

    Will Finasteride Protect My Donor Hair?

    May 27, 2020/by William Rassman, M.D./0 /Hair Loss Causes

    I’m a diffuse thinner and if I keep losing all of my hair I’ll be fully bald on top and have hair left on my sides. I’d like to protect my donor hair and prevent it from turning into a dupa situation.  So will taking finasteride right now help hair all over the head or no?I do not have dupa. Just diffuse thinning

    People either have DUPA or don’t have DUPA. Finasteride has no impact on the donor area, except if you have DUPA. It may reverse some of it in about 50% of patients with DUPA (Diffuse Unpatterned Alopecia).

    Why Is Dutasteride Not Approved by the FDA in the Us?

    May 26, 2020/by William Rassman, M.D./0 /Hair Loss Causes

    At this point, I doubt Dutasteride would ever be approved for hair loss as the 0.5mg is already generic. Why would a drug company go through expensive trials to get a second indication when the drug is off patent? They would have had to get it approved at the same time as BPH in order for them to make money.  For now, people in Canada and the USA or going to have to get it off label or order it online which sucks. Makes it harder to get for most of us.

    To get the FDA to approve dutasteride, the company that manufactures it must put in the application, and fight for it. They don’t seem to be interested.

    I Have Fine Hairs, so I Might Want to Use My Beard for a Hair Transplant, Thoughts?

    May 26, 2020/by William Rassman, M.D./0 /Hair Loss Causes

    I have very fine donor hair and not enough to cover my bald head. But I have a good beard. My question is, how much beard hair can a doctor extract from the face to use for transplantation? Personally for me I don’t care about my beard hair and I’d be happy to use it all for a transplant. Could that be possible?

    There are 30000 beard hairs which have a growth cycle similar to scalp hair (between 2-3 years). Of the 30,000 beard hairs on an average male, the best ones to use are the ones under the chin so it doesn’t look like you had any beard removed, but you should use scalp hair first, especially in the frontal leading edge of the hairline. You can probably get 15,000 hairs from the beard.

    Reddit poster took a vote on finasteride users

    May 25, 2020/by William Rassman, M.D./0 /Hair Loss Causes
    374 votes
    110
    29.4%
    Never taken it
    211
    56.4%
    Are taking it currently
    53
    14.2%
    Used to take it but stopped for whatever reason

    Voting closed 22 hours ago

    123
    Older Entries
    Page 1 of 6

    Videos

    Podcasts

    Ask Dr. Rassman

    * Your questions may be published (without your contact information).

    [contact-form-7 id=”27935″ title=”Sidebar Contact”]

    Over 21 million women and 35 million men in America suffer from hair loss. For many of these people, the psychological impact on their life is debilitating.

    Dr. Rassman is a world leading expert in hair loss with over 25 years of experience and over 50,000 satisfied clients.

    About

    This site exists to educate about hair loss and hair restoration.

    William R. Rassman, M.D.

    Categories

    • ACell
    • African American
    • Age
    • April Fools
    • Density
    • Diseases
    • Drugs
    • Drugs (Cause Hair Loss)
    • Favorites
    • Female Hair Loss
    • FUE
    • Hair Cloning
    • Hair Loss Causes
    • Hair Pieces / Systems
    • Hair Products
    • Hair Transplantation
    • Hairlines
    • Megasession
    • Other
    • Other Surgical Procedures
    • Personal Stories
    • Photos
    • Pigments
    • Podcasts
    • Post-Operative
    • Repair
    • Repost
    • Scalp MicroPigmentation
    • Scarring
    • Thinning
    • Tidbits
    • Training
    • Videos

    Archives

    • February 2023
    • January 2023
    • December 2022
    • November 2022
    • October 2022
    • September 2022
    • August 2022
    • July 2022
    • June 2022
    • May 2022
    • April 2022
    • March 2022
    • February 2022
    • January 2022
    • December 2021
    • November 2021
    • October 2021
    • September 2021
    • August 2021
    • July 2021
    • June 2021
    • May 2021
    • April 2021
    • March 2021
    • February 2021
    • January 2021
    • December 2020
    • November 2020
    • October 2020
    • September 2020
    • August 2020
    • July 2020
    • June 2020
    • May 2020
    • April 2020
    • March 2020
    • February 2020
    • January 2020
    • December 2019
    • November 2019
    • October 2019
    • September 2019
    • August 2019
    • July 2019
    • June 2019
    • May 2019
    • April 2019
    • March 2019
    • February 2019
    • January 2019
    • December 2018
    • November 2018
    • October 2018
    • September 2018
    • August 2018
    • July 2018
    • June 2018
    • May 2018
    • April 2018
    • March 2018
    • February 2018
    • January 2018
    • December 2017
    • November 2017
    • October 2017
    • September 2017
    • August 2017
    • July 2017
    • June 2017
    • May 2017
    • April 2017
    • March 2017
    • February 2017
    • January 2017
    • December 2016
    • November 2016
    • October 2016
    • June 2016
    • May 2016
    • April 2016
    • March 2016
    • February 2016
    • January 2016
    • December 2015
    • November 2015
    • October 2015
    • September 2015
    • August 2015
    • July 2015
    • June 2015
    • May 2015
    • April 2015
    • March 2015
    • February 2015
    • January 2015
    • December 2014
    • November 2014
    • October 2014
    • September 2014
    • August 2014
    • July 2014
    • June 2014
    • May 2014
    • April 2014
    • March 2014
    • February 2014
    • January 2014
    • December 2013
    • November 2013
    • October 2013
    • September 2013
    • August 2013
    • July 2013
    • June 2013
    • May 2013
    • April 2013
    • March 2013
    • February 2013
    • January 2013
    • December 2012
    • November 2012
    • October 2012
    • September 2012
    • August 2012
    • July 2012
    • June 2012
    • May 2012
    • April 2012
    • March 2012
    • February 2012
    • January 2012
    • December 2011
    • November 2011
    • October 2011
    • September 2011
    • August 2011
    • July 2011
    • June 2011
    • May 2011
    • April 2011
    • March 2011
    • February 2011
    • January 2011
    • December 2010
    • November 2010
    • October 2010
    • September 2010
    • August 2010
    • July 2010
    • June 2010
    • May 2010
    • April 2010
    • March 2010
    • February 2010
    • January 2010
    • December 2009
    • November 2009
    • October 2009
    • September 2009
    • August 2009
    • July 2009
    • June 2009
    • May 2009
    • April 2009
    • March 2009
    • February 2009
    • January 2009
    • December 2008
    • November 2008
    • October 2008
    • September 2008
    • August 2008
    • July 2008
    • June 2008
    • May 2008
    • April 2008
    • March 2008
    • February 2008
    • January 2008
    • December 2007
    • November 2007
    • October 2007
    • September 2007
    • August 2007
    • July 2007
    • June 2007
    • May 2007
    • April 2007
    • March 2007
    • February 2007
    • January 2007
    • December 2006
    • November 2006
    • October 2006
    • September 2006
    • August 2006
    • July 2006
    • June 2006
    • May 2006
    • April 2006
    • March 2006
    • February 2006
    • January 2006
    • December 2005
    • November 2005
    • October 2005
    • September 2005
    • August 2005
    • July 2005
    • June 2005
    • May 2005
    • April 2005
    • June 202
    • May 202

    Links

    Disclaimer

    This site is intended to educate the public on hair loss topics based on personal experience and opinions from Dr. William Rassman and contributing physician editors. Information provided on BaldingBlog.com should not be used for the purpose of medical diagnosis or treatment.

    Scroll to top